Australian-made disinfectant given a COVID-19-killing approved label claim

Following recent changes to the Guidelines for Disinfectants under Therapeutic Goods Order 104, which allow listed disinfectants to make validated claims to kill the SARS-CoV-2 (COVID-19) virus on surfaces, can confirm VIRACLEAN® , manufactured by the Whiteley Corporation, has the first newly approved label claim for killing the SARS-CoV-2 (COVID-19) virus on contaminated surfaces.

Viraclean® is a hospital-grade disinfectant intended for use on a wide range of surfaces which may be contaminated, better protecting patients and staff from the risk of SARS-CoV-2 (COVID-19) virus cross infection. (It is important to note that the product is a surface disinfectant and not intended for use directly on people, or for treating a patient.)

Given the capacity of COVID-19 to survive on hard and relatively soft surfaces for a prolonged period of time, cleaning and disinfecting those surfaces is incredibly important to limiting the spread of the virus.

Speaking about the newly-added label claim Dr Greg Whiteley, Chairman of Whiteley Corporation, noted that “This new label claim for Viraclean® against the virus responsible for the current pandemic will add to certainty around the level of hygiene in hospitals, particularly in Intensive Care Units, Emergency Departments, and a range of other clinical, medical and dental applications. These claims will also be applied to INSTRUMAX® PINK, which is used for Disinfection of Non-Critical Medical Devices in the hospital and healthcare sector.”

On a more technical comment Dr Whiteley said “The testing against Coronavirus in the case of this SARS-CoV-2 (COVID-19) relies on a number of surrogate viruses. This is important because using a surrogate protects the laboratory staff but allows a scientifically accurate representation of the disinfectant performance against all of the Coronaviruses including SARS-CoV-2 (COVID-19) virus. This approach allows the TGA to manage the regulatory aspects of both the approval and also market performance to ensure public health standards are maintained.”

/ADA Public Release. View in full here.